Biopharmaceutics of paclitaxel (taxol): Formulation, activity, and pharmacokinetics

Taxol®: Science and Applications

Volumn , Issue , 2021, Pages 237-258

  Straubinger, Robert M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85127721366     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (109)

1. Wani, M. C, Taylor, H.L., Wall, M.E., Coggon, P., and McPhail, A.T., The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia, J. Am Chem Soc, 93, 2325, 1971.
2. Rowinsky, E.K., Cazenave, L.A., and Donehower, R. C, Taxol-a novel investigational antimicrotubule agent, J. Natl. Cancer Inst., 82, 1247, 1990.
3. McGuire, W.P., Rowinsky, E.K., Rosenshein, N.B., Grumbine, F. C, Ettinger, D.S., Armstrong, D.K., and Donehower, R. C, Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms, Ann. Intern. Med., III, 273, 1989.
4. Holmes, F.A., Walters, R.S., Theriault, R.L., Forman, A.D., Newton, L.K., Räber, M.N., Buzdar, A.U., Frye, D.K., and Hortobagyi, G.N., Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer, J. Natl. Cancer Inst., 83, 1797, 1991.
5. Adams, J.D., Flora, K.P., Goldspiel, B.R., Wilson, J.W., and Finley, R., Taxol®: a history of pharmaceutical development and current pharmaceutical concerns, J. Natl. Cancer Inst. Monogr., 15, 141, 1993.
6. Tarr, B.D. and Yalkowsky, S.H., A new parenteral vehicle for the administration of some poorly water soluble anti-cancer drugs,/. Parenteral Sci. Technol, 41, 31, 1987.
7. Swindell, C.S. and Krauss, N.E., Biologically active taxol analogues with deleted A-ring side chain substituents and variable C-2' configurations, J. Med. Chem, 34. 1176, 1991.
8. Ringel, I. and Horwitz, S.B., Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol, J. Natl. Cancer Inst., 83. 288, 1991.
9. Mathew, A.E., Mejillano, M.R., Nath, J.P., Himes, R.H., and Stella, V.J., Synthesis and evaluation of some water-soluble prodrugs and derivatives of Taxol with antitumor activity, J. Med. Chem, 35, 145, 1992.
10. Stella, V.J., personal communication.
11. Sharma, U., Balasubramanian, S.V., and Straubinger, R.M., Pharmaceutical and physical properties of paclitaxel, submitted.
12. Deutsch, H.M., Gliński, J.A., Hernandez, M., Haugwitz, R.D., Narayanan, V.L., Suffness, M., and Zalkow, L.H., Synthesis of congeners and prodrugs. IIΙ. Water-soluble prodrugs of taxol with potent antitumor activity, J. Med. Chem., 32, 788, 1989.
13. Zhao, Z., Kingston, D.G. I., and Crosswell, A.R., Modified taxols. VI. Preparation of water-soluble prodrugs of taxol, J. Nat. Prod., 54, 1607, 1991.
14. Nicolau, K. C, Riemer, C, Kerr, M.A., Rideout, D., and Wrasidlo, W., Design, synthesis and biological activity of protaxols, Nature, 364, 464, 1993.
15. Georg, G.I., Boge, T. C, Cheruvallath, Z.S., Clowers, J.S., Harriman, G.C. B., Hepperle, M., Park, H., The medicinal chemistry of taxol, in Taxol®: Science and Applications, Suffness, M., ed., CRC Press, Boca Raton, FL, 317, 1995.
16. Vyas, D.M., Wong, H., Crosswell, A.R., Casazza, A.M., Knipe, J.O., Mamber, S.W., and Doyle, T.W., Synthesis and antitumor activity of water soluble taxol phosphates, Bioorg. Med. Chem Lett., 3, 1357, 1993.
17. Ueda, Y., Mikkilineni, A.B., Knipe, J.O., Rose, W. C, Casazza, A.M., and Vyas, D.M., Novel water soluble phosphate prodrugs of Taxol® possessing in vivo antitumor activity, Bioorg. Med. Chem Lett., 3, 1761, 1993.
18. Suffness, M., Taxol: from discovery to therapeutic use, Ann. Rep. Med. Chem., 28, 305, 1993.
19. Rose, W. C, Taxol: a review of its preclinical in vivo antitumor activity, Anti-Cancer Drugs, 3, 311, 1992.
20. NCI Investigational Drugs, Pharmaceutical Data, U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, 151, 1990.
21. Sharma, A. and Straubinger, R.M., unpublished observations.
22. Tarr, B.D., Sambandan, T.G., and Yalkowsky, S.H., A new parenteral emulsion for the administration of taxol, Pham Res 4,162,1987
23. Waugh, W.N., Trissel, L.A., and Stella, V. J" Stability, compatibility, and plasticizer extraction of taxol (NSC-125973) injection diluted in infusion solutions and stored in various containers, Am. J. Hosp. Pharm., 48, 1520, 1991.
24. Venkataramanan, R., Burckart, G.J., Ptachcinski, R.J., Blaha, R., Logue, L.W., Bahnson, A., Giam, C.S., and Brady, J.E., Leaching of diethylhexyl phthalate from polyvinyl chloride bags into intravenous cyclosporin solution, Am. J. Hosp. Pharm, 43, 2800, 1986.
25. Trissel, L.A. and Bready, B.B., Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection, Am. J. Hosp. Pharm, 49, 1716, 1992.
26. Trissel, L.A. and Martinez, J.F., Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection, Am. J. Hosp. Pharm, 50, 300, 1993.
27. Howrie, D.L., Ptachcinski, R.J., Griffith, B.P., Hardesty, R.J., Rosenthal, J.T., Burckart, G.J., and Venkataramanan, R., Anaphylactoid reactions associated with parenteral cyclosporine use: possible role of Cremophor EL, Drug Ititeli. Clin. Pharm., 19, 425, 1985.
28. O'Dwyer, P.J., King, S.A., Fortner, C.L., and Leyland-Jones, B., Hypersensitivity reactions to teniposide (VM-26): an analysis, J. Surg. Oncol., 4, 1262, 1986.
29. Rowinsky, E.K., Onetto, N., Canetta, R.M., and Arbuck, S.G., Taxol: the first of the taxanes, an important new class of antitumor agents, Semin. Oncol., 19, 646, 1992.
30. Dye, D. and Watkins, J., Suspected anaphylactic reaction to Cremophor EL., Br. Med. J., 280, 1353, 1980.
31. Lorenz, W., Riemann, H.J., Schmal, A., Schult, H., Lang, S., Ohmann, C, Weber, D., Kapp, B., Lüben, L., and Doenicke, A., Histamine release in dogs by Cremophor EL and its derivatives: oxyethylated oleic acid is the most effective constituent, Agents Actions, 7, 63, 1977.
32. Weiss, R.B., Donehower, R. C, Wiernik, P.H., Ohnuma, T., Gralla, R.J., Trump, D.L., Baker, J.R., VanEcho, D.A., VonHoff, D.D., and Leyland-Jones, B., Hypersensitivity reactions from taxol, J. Clin. Oncol., 8, 1263, 1990.
33. Rowinsky, E.K., Eisenhauer, E.A., Chaudhry, V., Arbuck, S.G., and Donehower, R. C, Clinical toxicities encountered with paclitaxel (Taxol®), Semin. Oncol., 20, 1, 1993.
34. Eisenhauer, E., ten Bokkel-Huinink, W., Swenerton, K., Mangioni, C, van der Burg, M., Kerr, I., Gianni, L., Buser, K., Vermorken, J., Onetto, N., Winograd, B., and Canetta, R., Toxicity of taxol: a European-Canadian trial of high vs. low dose and short vs. long infusion in ovarian cancer coordinated by the NCI Canada clinical trials group (NCIC CTG), 2nd Natl. Cancer Institute Workshop on Taxol and Taxus, Alexandria, VA, NCI, September 23-24, 1992.
35. Greenberger, P.A., Halwig, J.M., Patterson, R., and Wallemark, C.B., Emergency administration of radiocontrast media in high-risk patients, J. Allergy Clin. Immunol., 77, 630, 1986.
36. Onetto, N., Rozencweig, M., and Canetta, R., An integrated analysis of the safety of single agent taxol, J. Natl. Cancer Inst. Monogr., in press.
37. Arbuck, S.G., Canetta, R., Onetto, N., and Christian, M. C, Current dosage and schedule issues in the development of paclitaxel (Taxol®), Semin. Oncol., 20, 31, 1993.
38. Runowicz, C.D., Wiernik, P.H., Einzig, A.I., Goldberg, G.L., and Horwitz, S.B., Taxol in ovarian cancer, Cancer, 71, 1591, 1993.
39. Swenerton, K., Eisenhauer, R., and ten Bokkel-Huinink, W., Taxol in relapsed ovarian cancer: high vs. low dose and short vs. long infusion: a European-Canadian study coordinated by the NCI Canada Clinical Trials Group, Proc. Am. Soc. Clin. Oncol., 12, (abstr.), 256, 1993.
40. 2-antagonist drug interactionsxoncepts and implications, J. Clin. Gastroenterol., 5, 95, 1983.
41. Monsarrat, B., Mariel, E., Cros, S., Garés, M., Guénard, D., Guéritte-Voegelein, F., and Wright, M., taxol metabolism. Isolation and identification of three major metabolites of taxol in rat bile, Drug Metab. Dispos., 18, 895, 1990.
42. Jamis-Dow, C.A., Klecker, R.W., Katki, A.G., and Collins, J.M., Metabolism of taxol by human liver microsomes and effect of inhibitors, Proc. Ann. Meet. Am Assoc. Cancer Res., 34, A2198, 1993.
43. Rowinsky, E.K. and Donehower, R. C, The clinical pharmacology of paclitaxel (TAXOL®), Semin. Oncol, 20, 16, 1993.
44. Cresteil, T., Monsarrat, B., Alvinerie, P., Tréluyer, J.M., Viera, I., and Wright, M., Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation, Cancer Res., 54, 386, 1994.
45. 3H-taxol in the Sprague-Dawley rat. Drug Metab. Disposition 22: 254-258, 1994.
46. Wiernik, P.H., Schwartz, E.L., Einzig, A., Strauman, J.J., Lipton, R.B., and Dutcher, J.P., Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma, J. Clin. Oncol, 5, 1232, 1987.
47. Longnecker, S.M., Donehower, R. C, Cates, A.E., Chen, T.-L., Brundrett, R.B., Growchow, L.B., Ettinger, D.S., and Colvin, M., High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial, Cancer Treat. Rep., 71, 53, 1987.
48. Γ acid glycoprotein, Res. Commun. Chem. Pathol. Pharmacol, 80, 337, 1993.
49. Pastan, I.H. and Gottesmann, M.M., Molecular biology of multidrug resistance in human cells, Imp. Adv. Oncol, 1, 3, 1988.
50. Georges, E., Sharom, F.J., and Ling, V., Multidrug resistance and chemosensitization: therapeutic implications for cancer chemotherapy, Adv. Pharmacol, 21, 185, 1990.
51. Roy, S.N. and Horwitz, S.B., A phosphoglycoprotein associated with taxol resistance in J774.2 cells, Cancer Res., 45, 3856, 1985.
52. Waud, W.R., Gilbert, K.S., Harrison, S.D., Jr., and Griswold, D.P., Jr., Cross-resistance of drug-resistant murine P388 leukemias to taxol in vivo, Cancer Chemother. Pharmacol, 31, 255, 1992.
53. Woodcock, D.M., Jefferson, S., Linsenmeyer, M.E., Crowther, P.J., Chojnowski, G.M., Williams, B., and Ber-toncello, I., Reversal of the multidrug resistance phenotype with Cremophor EL®, a common vehicle for water-insoluble vitamins and drugs, Cancer Res., 50, 4199, 1990.
54. Webster, L., Linsenmeyer, M., Millward, M., Morton, C, Bishop J., and Woodcock, D., Measurement of Cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype, J. Natl. Cancer Inst., 85, 1685, 1993.
55. Fjällskog, M.-L., Frii, L., and Bergh, J., Is Cremophor EL, solvent for paclitaxel, cytotoxic?, Lancet, 342, 873, 1993.
56. 3H-azidophine: relation to lipophilicity and inhibition of daunorubicin transport in multidrug resistant cells, Br. J. Cancer, 67, 226, 1993.
57. Markman, M., Rowinsky, E., Hakes, T., Reichman, B., Jones, W., Lewis, J.L., Jr., Rubin, S., Curtin, J., Barakat, R., Phillips, M., Hurowitz, L., Almadrones, L., and Hoskins, W., Phase I trial of intraperitoneal taxol: a Gynecologic Oncology Group study, J. Clin. Oncol, 10, 1485, 1992.
58. Wiemik, P.H., Schwartz, E.L., Strauman, J.J., Dutcher, J., Lipton, R., and Paietta, E., Phase I clinical and pharmacokinetic study of taxol, Cancer Res., 47, 2486, 1987.
59. Burke, T.G. and Chandraesekar, R., Liposomal formulations of taxol: physical characteristics, 2nd Natl. Cancer Institute Workshop on Taxol and Taxus, NCI, Alexandria, VA, September 23-24, 1992.
60. Flynn, G.L., Solubility concepts and their application to the formulation of pharmaceutical systems, J. Parenteral Sci. Technol, 38, 202, 1984.
61. Yalkowski, S.H. and Valvani, S. C, Precipitation of solubilized drugs due to injection or dilution, Drug Intell. Clin. Pharm., 11,417, 1977.
62. Bissery, M. C, Guénard, D., Guéritte-Voegelein, F., and Lavelle, F., Experimental antitumor activity of taxotere (RP 56976, NSC 628503) a Taxol analogue, Cancer Res., 51, 4845, 1991.
63. New compositions containing taxane derivatives, French Patent No. 65094 to Rhône Poulenc Rorer SA, Antony, France.
64. New compositions containing taxane derivatives, French Patent No. 65109 to Rhône Poulenc Rorer SA, Antony, France.
65. Bisset, D., Setanoians, A., Cassidy, J., Graham, M.A., Chadwick, G.A., Wilson, P., Auzannet, V., Le Bail, N., Kaye, S.B., and Kerr, D.J., Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion, Cancer Res., 53, 523, 1993.
66. Extra, J.-M., Rousseau, F., Bruno, R., Clavel, M., Le Bail, N., and Marty, M., Phase I and pharmacokinetic study of taxotere (RP 56976; NSC 628503) given as a short intravenous infusion, Cancer Res., 53, 1037, 1993
67. Boven, E., Venema-Gaberscek, E., Erkelens, C.A. M., Bissery, M. C, and Pinedo, H.M., Antitumor activity of taxotere (RP 56976, NSC 628503), a new taxol analog, in experimental ovarian cancer, Ann. Oncol, 4, 321, 1993.
68. Fumoleau, P., Chevallier, B., Kerbrat, P., Dieras, V., Le Bail, N., Fumoleau, M.P., and van Glabbeke, M., First line chemotherapy with Taxotere™ in advanced breast cancer: a Phase II study of the EORTC clinical screening group, Proc. Am. Soc. Clin. Oncol, 12, 56a, 1993.
69. Irvin, B., Bums, H., Kuhn, J., Kalter, S., Smith, L., Rodriguez, G., Weiss, G., Eckardt, J., Cook, G., Wall, J., Le Bail, N., Bayssas, M., and Von Hoff, D., Phase I trial for a 3 and 3 hour infusion of taxotere, Proc. Am. Soc. Clin. Oncol, 12, 137a, 1993.
70. Aapro, M., Pujade-Lauraine, E., Lhomme, C, Lentz, M.-A., Le Bail, N., Fumoleau, P., and Chevallier, B., Phase II study of Taxotere™ in ovarian cancer, Proc. Am. Soc. Clin. Oncol, 12, 256a, 1993.
71. Burns, H., Eckardt, J., Fields, S., Rodriguesz, G., Smith, L., Thurman, A., Peacock, N., Kuhn, J., Hodges, S., Bellet, R., Bayssas, M., Le Bail, N., and Von Hoff, D., Phase II trials of taxotere in patients with non-small cell lung cancer, Proc. Am. Soc. Clin. Oncol, 12, 335a, 1993.
72. Schrijvers, D., Wanders, J., Dirix, L., Prove, A., Vonck, I., van Oosterom, A., and Kaye, S., Coping with toxicities of docetaxel (Taxotere™), Ann. Oncol, 4, 610, 1993.
73. Mayhew, E. and Papahadjopoulos, D., Therapeutic applications of liposomes, in Liposomes, Ostro, M.J., Ed., Marcel Dekker, New York, 1983, 289.
74. Popescu, M. C, Swenson, C.E., and Ginsberg, R.S., Liposome-mediated treatment of viral, bacterial, and protozoal infections, in Liposomes: From Biophysics to Therapeutics, Ostro, M.J., Ed., Marcel Dekker, New York, 1987, 219.
75. Szoka, F. C, Jr., Liposomal drug delivery: current status and future prospects, in Membrane Fusion, Wilschut, J. and Hoekstra, D., Eds., Marcel Dekker, New York, 1991, 845.
76. Fielding, R.M., Liposomal drug delivery: advantages and limitations from a clinical pharmacokinetic and therapeutic perspective, Clin. Pharmacokinet., 21, 155, 1991.
77. Martin, F.J., Pharmaceutical manufacturing of liposomes, in Specialized Drug Delivery Systems, Tyle, P., Ed., Marcel Dekker, 267. New York, 1990
78. Gregoriadis, G., Ed., Liposome Technology, Vol. 1 to 3, CRC Press Boca Raton, FL., 1984.
79. Ostro, M.J., Ed., Liposomes from Biophysics to Therapeutics, Marcel Dekker, New York, 1987.
80. Gregoriadis, G., Ed., Liposomes As Drug Carriers, John Wiley & Sons, New York, 1988.
81. Szoka, F. C, Jr. and Papahadjopoulos, D., Comparative properties and methods of preparation of lipid vesicles (liposomes), Annu. Rev. Biophys., Bioeng., 9, 467, 1980.
82. Bartoli, M.-H., Boitard, M., Fessi, H., Beriel, H., Devissaguet, J.-H., Picot, F., and Puisieux, F., In vitro and in vivo antitumor activity of free and encapsulated taxol, J. Microencapsulation, 7, 191, 1990.
83. Riondel, J., Jacrot, M., Fessi, H., Puisieux, F., and Poiter, P., Effects of free and liposome-encapsulated taxol on two brain tumors xenografted into nude mice, In Vivo, 6, 23, 1992.
84. Rafaeloff, R., Husain, S.R., and Rahman, A., Liposome-encapsulated taxol (LET) is an effective modality to circumvent multidrug resistance (MDR) phenotype, Proc. Annu. Meet. Am Assoc. Cancer Res., 33, A2883. 1992.
85. Straubinger, R.M., Sharma, A., Murray, M., and Mayhew, E., Novel Taxol formulations: taxol-containing liposomes, J. Natl. Cancer Inst. Monogr., 15, 69, 1993.
86. Sharma, A., Mayhew, E., and Straubinger, R.M., Antitumor effect of taxol-containing liposomes in a taxol-resistant murine tumor model, Cancer Res., 54, 5877, 1993.
87. Szoka, F. C, Jr. and Papahadjopoulos, D., Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation, Proc. Natl. Acad. Set, 75, 4194, 1978.
88. Olson, F., Hunt, C.A., Szoka, F. C, Jr., Vail, W.J., and Papahadjopoulos, D., Preparation of liposomes of defined size by extrusion through polycarbonate membranes, Biochim. Biophys. Acta, 557, 9, 1979.
89. Sharma, A. and Straubinger, R.M., Novel Taxol formulations: preparation and characterization of taxol-containing liposomes, Pharm Res., in press.
90. Bangham, A., Standisti, M., and Watkins, J., Diffusion of univalent ions across the lamellae of swollen phospholipids, J. Mol. Biol, 13, 238, 1965.
91. Straubinger, R.M. and Papahadjopoulos, D., Liposomes as carriers for intracellular delivery of nucleic acids, in Methods in Enzymology, Vol. 101, Wu, R., Grossman, L., and Moldave, K., Eds., Academic Press, New York, 1982,512.
92. Perez-Soler, R., Lopez-Berestein, G., Lautersztain, J., al-Baker, S., Francis, K., Macias-Kiger, D., Räber, M.N., and Khokhar, A.R., Phase I clinical and pharmacological study of liposome-entrapped cis-bis-neodecanoato-trans-R, R-l,2-diaminocyclohexane platinum(II), Cancer Res., 50, 4254, 1990.
93. Sharma, A., Lopez Straubinger, N.G., and Straubinger, R.M., Modulation of human ovarian tumor cell sensitivity to N-(Phosphonacetyl)-L-aspartate (PALA) by liposome drug carriers, Pharm. Res., 10, 1434, 1993.
94. Eiseman, J.L., Eddington, N., Leslie, J., MacAuley, C, Sentz, D., Kujawa, J., Zuhowski, M., Haidir, S., Young, D., and Egorin, M.J., Pharmacokinetics and development of a physiological model of taxol in CD2F1 mice, 2nd Nad. Cancer Institute Workshop on Taxol and Taxus, NCI, Alexandria, VA, September 23-24, 1992.
95. Eddington, N., Eiseman, J., Leslie, J., MacAuley, C, Sentz, D., Kujawa, J., Haidar, S., Habib, Y., Young, D., and Egorin, M., Taxol pharmacokinetics (PK) after various routes of administration to CD2F1 mice, Pharm. Res., 9, S268, 1992.
96. Leyland-Jones, B., Targeted drug delivery, Semin. Oncol, 20, 12, 1993.
97. Strattan, C.E., Cyclodextrins and biological macromolecules, Biopharmaceutics, 52, 44, 1991.
98. Heindel, N.D., Egolf, R.A., and Stefely, J.S., Effect of liposomes and cyclodextrin entrapment on retardation of glutathione decomposition of nitroimidazolyl sulfones, J. Pharm Sci., 79, 862, 1990.
99. M Loftsson, T., Estes, K.S., Lin, J.-L., Fridriksdottir, H., and Bodor, N., Effect of various cyclodextrins on solution stability and dissolution rate of doxorubicin hydrochloride, Int. J. Pharm, 79, 289, 1992.
100. Brewster, M.E., Hora, M.S., Simpkins, J.W., and Bodor, N., Use of 2-hydroxypropyl-ß-cyclodextrin as a solu-bilizing and stabilizing excipient for protein drugs, Pharm. Res., 8, 792, 1991.
101. Pitha, J., Milecki, J., Fales, H., Pannell, L., and Uekama, K., Hydroxypropyl-ß-cyclcKiextrin: preparation and characterization; effects on solubility of drugs, Int. J. Pharm., 29, 73, 1986.
102. Szejtli, J., Cyclodextrins in drug formulations. I, Pharm Technol, 3, 15, 1991.
103. Brown, T., Havlin, K., Weiss, G., Cagnola, J., Koeller, J., Kuhn, J., Rizzo, J., Craig, J., Phillips, J. and VonHoff, D., A phase I trial of taxol given by 6-hour infusion, J. Clin. Oncol 9, 1261, 1991.
104. Grem, J.L., Tutsch, K.D., Simon, K.J., Alberti, D.B., Willson, J.V. K., Tormey, D. C, Swaminathan, S., and Trump, D.L., Phase I study of taxol administered as a short iv infusion daily for 5 days, Cancer Treat Rep., 71, 1179, 1987.
105. Rowinsky, E.K., Burke, P.J., Karp, J.E., Tucker, R.W., Ettinger, D.S. and Donehower, R.C. Phase I and pharmacodynamic study of taxol in refractory acute leukemias. Cancer Res. 49: 4640-4647, 1989.
106. Sonnichsen, D.S., Hurwitz, C.A., Pratt, C.B., Shuster, J.J., and Relling, M.V., Saturable pharmacokinetics and taxol pharmacodynamics in children with solid tumors, J. Clin. Oncol, 12, 532, 1994.
107. Berg, S.L., Cowan, K.H., Balis, F.M., Fisherman, J.S., Denicoff, A.M., Hillig, M., Poplack, D.G., and O'Shaughnessy, J.A., Pharmacokinetics of taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion, / Natl. Cancer Inst, 86, 143, 1994.
108. Rizzo, J., Riley, C, VonHoff, D., Kuhn, J., Phillips, J., and Brown, T., Analysis of anticancer drugs in biological fluids: determination of taxol with application to clinical pharmacokinetics, J. Pharm. Biomed. Anal, 8, 159, 1990.
109. 3H-taxol in the rat, 2nd Natl. Cancer Institute Workshop on Taxol and Taxus, NCI, Alexandria, VA, September 23-24, 1992.